Pharmacogenomics and "Individualized Drug Therapy": High Expectations and Disappointing Achievements

American Journal of PharmacoGenomics

Volumn 3, Issue 6, 2003, Pages 361-370

  Nebert, Daniel W ^a   Jorge Nebert, Lucia ^b   Vesell, Elliot S ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSIDAD DE PANAMÁ   (Panama)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THIOPURINE METHYLTRANSFERASE;

BIOSAFETY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; INDIVIDUALITY; MEDICAL PRACTICE; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PHYSICIAN; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY;

EID: 0347185032     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303060-00002     Document Type: Review

References (70)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
2. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37
3. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49
4. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003; 348: 553-6
5. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37 Suppl. 1: 40S-8S
6. Christensen M, Andersson K, Dalen P, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003; 73: 517-28
7. Judson R. Using multiple drug exposure levels to optimize power in pharmacogenetic trials. J Clin Pharmacol 2003; 43: 816-24
8. Nebert DW, Roe AL, Vandale SL. et al. NAD(P)H:quinone oxidoreductase (NQOI) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 2002; 4: 62-70
9. Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and their role in cancer chemotherapy. Drug Resist Updat 2003; 6: 71-84
10. Wang L, Sullivan W, Toft D, et al. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003; 13: 555-64
11. Zhang EY, Knipp GT, Ekins S, et al. Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev 2002; 34: 709-50
12. Perez, DM. The evolutionarily triumphant G-protein-coupled receptor. Mol Pharmacol 2003; 63: 1202-5
13. Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003; 13: 525-34
14. Lee A, Rana BK, Schiffer HH, et al. Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family. Genomics 2003; 81: 245-8
15. Vesell ES, Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 2000; 40: 930-8
16. Ncbert DW. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 2000; 410: 107-20
17. Halushka MK, Fan JB, Bentley K, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22: 239-47
18. Nickerson DA, Taylor SL, Weiss KM, et al. DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nat Genet 1998; 19: 233-40
19. Ncbcrt DW. Proposal for an allele nomenclature system based on the evolutionary divergence of haplotypes. Hum Mutat 2002; 20: 463-72
20. Salishury BA, Pungliya M, Choi JY, et al. SNP and haplotype variation in the human genome. Mutat Res 2003; 526: 53-61
21. Carlson CS, Eberle MA, Rieder MJ, et al. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet 2003; 33: 518-21
22. Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 2000; 10: 279-90
23. Nebert DW, Menon AG. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics J 2001; 1: 19-22
24. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002; 1: 541-9
25. Nebert DW. Transcription factors and cancer: an overview. Toxicology 2002; 181-182: 131-41
26. Srivastava M, Eidelman O, Leighton X, et al. ANX7 is required for nutritional control of gene expression in mouse pancreatic islets of Langerhans. Mol Med 2002; 8: 781-97
27. Smith AG, Davies R, Dalton TP, et al. Intrinsic hepatic phenotype associated with the Cypla2 gene as shown by cDNA expression microarray analysis of the knockout mouse. Environ Health Perspect 2003; 111: 855-61
28. Puga A, Maier A, Medvedovic M. The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem Pharmacol 2000; 60: 1129-42
29. Cherkaoui-Malki M, Meyer K, Cao WQ, et al. Identification of novel peroxisome proliferator-activated receptor alpha (PPAR) target genes in mouse liver using cDNA microarray analysis. Gene Expr 2001; 9: 291-304
30. Cheok MH, Yang W, Pui CH, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003; 34: 85-90
31. Cardon LR, Abecasis GR. Using haplotype blocks to map human complex trait loci. Trends Genet 2003; 19: 135-40
32. Ke X, Cardon LR. Efficient selective screening of haplotype tag SNPs. Bioinformatics 2003; 19: 287-8
33. Clark AG, Nielsen R, Signorovitch J, et al. Linkage disequilibrium and inference of ancestral recombination in 538 single-nucleotide polymorphism clusters across the human genome. Am J Hum Genet 2003; 73: 285-300
34. Calafell F, Classifying humans. Nat Genet 2003; 33: 435-6
35. Zhivotovsky LA, Rosenberg NA, Feldman MW. Features of evolution and expansion of modern humans, inferred from genomewide microsatellite markers. Am J Hum Genet 2003; 72: 1171-86
36. Hartl DL, Clark AG. Principles of population genetics. Sunderland (MA): Sinauer Associates. 1997
37. Wang N, Akey JM, Zhang K, et al. Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation. Am J Hum Genet 2002; 71: 1227-34
38. Thompson E. Pedigree analysis in human genetics. Baltimore (MD): Johns Hopkins University Press, 1986
39. Arnheim N, Calabrese P, Nordborg M. Hot and cold spots of recombination in the human genome: the reason we should find them and how this can be achieved. Am J Hum Genet 2003; 73: 5-16
40. Anderson EC, Novembre J. Finding haplotype block boundaries by using the minimum-description-length principle. Am J Hum Genet 2003; 73: 336-54
41. Smith RA, Ho PJ, Clegg JB, et al. Recombination breakpoints in the humun β-globin gene cluster. Blood 1998; 92: 4415-21
42. Jeffreys AJ, Kauppi L, Neumann R. Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex. Nat Genet 2001; 29: 217-22
43. McKeigue PM. Mapping genes underlying ethnic differences in disease risk by linkage disequilibrium in recently admixed populations. Am J Hum Genet 1997; 60: 188-96
44. Bamshad MJ, Wooding S, Watkins WS, et al. Human population genetic structure and inference of group membership. Am J Hum Genet 2003; 72: 578-89
45. Nebert DW. Pharmacogenetics: 65 candles on the cake. Pharmacogenetics 1997; 7: 435-40
46. Snyder LH. Studies in human inheritance: IX. the inheritance of taste deficiency in man. Ohio J Sci 1932; 32: 436-68
47. Kalow W, Gunn DR. Some statistical data on atypical cholinesterase of human serum. Ann Hum Genet 1959; 23: 239-50
48. Allison AC. Glucose-6-phosphate dehydrogenase deficiency in red blood cells of East Africans. Nature 1960; 186: 531-2
49. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 1960; 2: 485-91
50. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 11: 584-6
51. Geldmacher-von Mallinckrodt M, Hommel G, Dumbach J. On the genetics of the human serum paraoxonase (EC 3.1.1.2). Hum Genet 1979; 50: 313-26
52. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62
53. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-6
54. Blum M, Grant DM, McBride OW, et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localizataion, and functional expression. DNA Cell Biol 1990; 9: 193-203
55. Oscarson M, Ingelman-Sundberg M, Daly AK, et al. Human cytochrome P450 (CYP) alleles [online]. Available from URL: http://www.imm.ki.se/CYPalleles/ [Accessed 2003 Sep 28]
56. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra-rapid metabolism of dcbrisoquine. Proc Natl Acad Sci U S A 1993; 90: 11825-9
57. Weinshilboum RM, Ottcrness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19-52
58. McLeod HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 567-72
59. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-14
60. Vesell ES. Therapeutics lessons from pharmacogenetics. Ann Intern Med 1997; 126: 653-5
61. van Aken J, Schmedders M, Feuerstein G, et al. Prospects and limits of pharmacogenetics, the thiopurine methyltransferase (TPMT) experience. Am J Pharmacogenomics 2003; 3: 147-55
62. Nebert DW, Jorge-Nebert LF. Pharmacogenetics and pharmacogenomics. In: Rimoin DL, Connor JM. Pyeritz RE, et al., editors. Emery & Rimoin's principles and practice of medical genetics. 4th ed. London: Churchill Livingstone. 2002: 590-631
63. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PONI) phenotype is a better predictor of vascular disease than is PONI(192) or PONI(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-7
64. Page GP, George V, Go RC, et al. "Are we there yet?": deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. Am J Hum Genet 2003; 73: 711-9
65. MacGregor PF. Gene expression in cancer: the application of microarrays. Expert Rev Mol Diagn 2003; 3: 185-200
66. Domchek SM, Weber BL. Recent advances in breast cancer biology. Curr Opin Oncol 2002; 14: 589-93
67. Righetti PG, Castagna A, Antonucci F, et al. The proteome: anno Domini 2002. Clin Chem Lab Med 2002; 41: 425-38
68. Plumb RS, Stumpf CL, Gorenstein MV, et al. Metabonomics: the use of electrospray mass spectrometry coupled to reversed-phase liquid chromatography shows potential for the screening of rat urine in drug development. Rapid Commun Mass Spectrom 2002; 6: 1991-6
69. Reo NV. NMR-based metabolomics. Drug Chem Toxicol 2002; 25: 375-82
70. Freimer N, Sabatti C. The human phenome project. Nat Genet 2003; 34: 15-21